Gilead Sciences CDR (CAD Hedged)

Price Chart

Risk-Adjusted Performance

Gilead Sciences CDR (CAD Hedged) (GILD) Price Performance

Gilead Sciences CDR (CAD Hedged) (GILD) trades on Toronto Stock Exchange in CAD. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at CAD26.60, down 2.28% from the previous close.

Over the past year, GILD has traded between a low of CAD22.15 and a high of CAD31.80. The stock has gained 19.8% over this period. It is currently 16.4% below its 52-week high.

Gilead Sciences CDR (CAD Hedged) has a market capitalization of $231.57B, with a price-to-earnings ratio of 483.44.

About Gilead Sciences CDR (CAD Hedged)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.